Skip to main content
. Author manuscript; available in PMC: 2023 Apr 26.
Published in final edited form as: Transl Res. 2020 Mar 16;220:98–113. doi: 10.1016/j.trsl.2020.03.009

Table 1. Select HDTs developed for select intracellular bacteria.

HIF-1α, hypoxia inducible factor-1α; Akt, protein kinase B; TLR-3, toll-like receptor 3; Poly (I:C), Polyinosine:polycytosine; ROS, reactive oxygen species; ATRA, all-trans retinoic acid; NPC2, NPC intracellular cholesterol transporter; mTORC1, mammalian target of rapamycin complex 1

Bacteria HDTs Antibacterial Mechanism Ref
M. tb Imatinib Tyrosine kinase inhibitor 12
M. tb Metformin Mitochondrial ROS production 13
M. tb Doxycycline Matrix metalloproteinase inhibitor 10
M. tb ATRA Lysosomal acidification via NPC2 14
M. tb Nitazoxanide Autophagy inducing via mTORC1 15
M. tb Dexamethasone Unknown 16
E. coli AKB 2924 HIF-1α stabilizing agent 17,18
E. coli
S. aureus
Clavanin-MO Leukocyte recruitment and immune mediator production 19
E. coli Lactoferrin Neutrophil recruitment 20
S. Typhimurium
S. Typhi
F. tularensis
AR-12 Autophagy inducing 21,22,24
S. Typhimurium Mibefradil
Haloperidol
Unknown 23
F. tularensis Poly (I:C) TLR3 agonist 25